Neurotoxic Methamphetamine Doses Alter CDCel-1 Levels and Its Interaction with Vesicular Monoamine Transporter-2 in Rat Striatum

Heli Chauhan,Nicholas Carruthers,Paul Stemmer,Bernard Schenider,Anna Moszczynska

DOI: https://doi.org/10.1101/2024.07.21.604458

2024-07-23

Abstract:In recent years, methamphetamine METH misuse in the US has been rapidly increasing and there is no FDA-approved pharmacotherapy for METH use disorder (MUD). In addition to being dependent on the drug, people with MUD develop a variety of neurological problems related to the toxicity of this drug. A variety of molecular mechanisms underlying METH neurotoxicity has been identified, including dysfunction of the neuroprotective protein parkin. However, it is not known whether parkin loss of function within striatal dopaminergic (DAergic) terminals translates into a decrease in DA storage capacity. This study examined the relationship between parkin, its substrate cell division cycle related-1 (CDCrel-1), and vesicular monoamine transporter-2 (VMAT2) in METH neurotoxicity in male Sprague Dawley rats. To also assess individual differences in response to METH’s neurotoxic effects, a large group of rats was treated with binge METH or saline and sacrificed 1h or 24h later. This study is the first to show that binge METH alters the levels and subcellular localization of CDCrel-1 and that CDCrel-1 interacts with VMAT2 and increases its levels at the plasma membrane. Furthermore, we found wide individual differences in the responses of measured indices to METH. Proteomic analysis of VMAT-2-associated proteins revealed upregulation of several proteins involved in the exocytosis/endocytosis cycle. The results suggest that at 1h after METH binge, DAergic neurons are engaged in counteracting METH-induced toxic effects, including oxidative stress- and hyperthermia-induced inhibition of synaptic vesicle cycling, with the responses varying between individual rats. Studying CDCrel-1, VMAT2, and other proteins in large groups of outbred rats can help define individual genetic and molecular differences in responses to METH neurotoxicity which, in turn, will aid treating humans suffering from METH use disorder and its neurological consequences.

Neuroscience

What problem does this paper attempt to address?

The paper primarily explores how neurotoxic doses of methamphetamine (METH) affect the levels of CD cell cycle-related protein 1 (CDCrel-1) in the rat striatum and its interaction with vesicular monoamine transporter 2 (VMAT2).

Specifically, the study focuses on the following key points:
1. **Background**: In recent years, methamphetamine abuse has rapidly increased in the United States, but there are currently no FDA-approved medications for treating methamphetamine use disorder (MUD). Methamphetamine abuse can lead to various neurological issues, including an increased risk of Parkinson's disease.
2. **Subjects**: The experiment used male Sprague-Dawley rats as models, analyzing them at different time points (1 hour or 24 hours) after administering methamphetamine or saline.
3. **Objective**: The study aims to explore how methamphetamine alters the levels and subcellular localization of CDCrel-1, and to investigate how CDCrel-1 interacts with VMAT2 and how this interaction affects VMAT2 levels on the cell membrane.
4. **Findings**: The study reveals for the first time that methamphetamine causes changes in CDCrel-1 levels and enhances its interaction with VMAT2, and that CDCrel-1 can increase VMAT2 levels on the cell membrane. Additionally, the study found significant individual differences in response to methamphetamine.
5. **Conclusion**: The results indicate that 1 hour after methamphetamine abuse, dopaminergic neurons are struggling to counteract the toxic effects induced by methamphetamine, including oxidative stress and inhibition of synaptic vesicle cycling. These findings help define individual genetic and molecular differences, which may aid in developing treatments for methamphetamine use disorder and its neurological consequences.